Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
The presentation will include an overview of the Company, an update onclinical trials for VELCADE(R) (bortezomib) for Injection and other productcandidates, and a review of upcoming milestones. The presentation will bedelivered at 9:20 a.m. ET (2:20 p.m. GMT) on Thursday, September 20, 2007 fromthe Merrill Lynch Financial Centre in London, England. The presentation willbe archived for 30 days.
Advertisement
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical companybased in Cambridge, Mass., markets VELCADE, a novel cancer product, and has arobust clinical development pipeline of product candidates. The Company'sresearch, development and commercialization activities are focused in twotherapeutic areas: oncology and inflammation. By applying its knowledge ofthe human genome, understanding of disease mechanisms and industrialized drugdiscovery platform, Millennium is developing an exciting pipeline ofinnovative product candidates. The Company's website ishttp://www.millennium.com.
Editors' Note: This press release is also available under the Mediasection of the Company's website at: http://www.millennium.com.
Contact:
Kyle Kuvalanka
(617) 761-4734
SOURCE Millennium Pharmaceuticals, Inc.
